The latest Investing Matters Podcast episode with multi-award-winning fund manager and international bestselling author Lee Freeman-Shor has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE
Bradda Head  Lithium exceeds targets, secures US$3 million royalty and moves closer to production
Bradda Head Lithium exceeds targets, secures US$3 million royalty and moves closer to productionView Video
IntelliAM aiming for significant growth with £5 million Aquis IPO
IntelliAM aiming for significant growth with £5 million Aquis IPOView Video

Latest Share Chat

Pin to quick picksSanofi Share News (SAN.PA)

Share Price Information for Sanofi (SAN.PA)

Euronext Paris
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 90.94
Bid: 93.35
Ask: 93.36
Change: -0.13 (-0.143%)
Spread: 0.01 (0.011%)
Open: 91.24
High: 91.56
Low: 90.53
Prev. Close: 90.23
SAN.PA Live PriceLast checked at -
  • This share is an international stock.

Watchlists are a member only feature

Login to your account

STOXX 600 closes at record high on earnings, rate cut optimism

Fri, 10th May 2024 17:21

Rio Tinto considered bid for BHP-target Anglo American -report

*

Green energy production in Italy boosts Enel's Q1 results

*

Medical gear maker Getinge plummets after FDA's safety warning

*

Italy industry output posts unexpected fall in March

May 10 (Reuters) - Europe's main stock index closed at a record high on Friday, on track for its biggest weekly gain since late January, as risk appetite was bolstered by growing bets on interest rate cuts in the region and a strong earnings season.

The pan-European STOXX 600 ended 0.7% higher, with indexes in major economies Germany and France finishing at record highs.

European shares have resumed their record-breaking rally, with the STOXX 600 notching a 3% weekly gain, after investors took a breather in April.

The euphoria around artificial intelligence and monetary policy easing, among others, had sparked bumper gains in the region's stocks since late 2023.

Highlighting Europe's divergence from the U.S. Federal Reserve and boosting equities, the Bank of England hinted at summer rate cuts and Sweden's Riksbank delivered its first cut since 2016 earlier this week.

Minutes from the ECB's April policy meeting showed that policymakers favoured kicking off the monetary policy easing cycle in June, while remaining confident that inflation is on track to fall back to 2% next year.

"Looking beyond June, the path for the bank is anything but clear. The risk of reflation has clearly increased," said Carsten Brzeski, global head of macro at ING Research.

"Any signs of reflation and also stronger economic activity would limit the ECB's room for manoeuvre."

Leading sectoral gains, utilities advanced 1.4%, with Italy's Enel climbing 3.8% following a higher first-quarter core profit. Portugal's largest utility firm EDP climbed 3.9% after a bigger-than-expected jump in first-quarter net profit.

Retailers added 1.5%, with Zalando rising 3.3% after Berenberg upgraded the German online retailer to "buy" from "hold".

Among M&A developments, shares of BBVA and Sabadell were up 1.3% and 0.5%, respectively, as investors assessed the developments around the first hostile banking takeover bid in Spain since the 1980s.

Anglo American advanced 1.4% after a report said mining giant Rio Tinto had considered an offer for the British miner.

Sanofi rose 1.3% after Novavax struck a licensing deal of up to $1.2 billion with French drugmaker for its COVID-19 vaccine in exchange for a stake that valued the U.S. biotech firm at double its current market capitalisation.

On the flip side, Getinge slumped 8.8% to the bottom of the STOXX after the U.S. FDA issued a warning on the safety of two of the Swedish medical equipment maker's heart devices.

Symrise shed 1.4% after Berenberg downgraded the German flavour and fragrance maker to "hold" from "buy".

On the data front, Italian industrial output was much weaker than expected in March, extending the pain for the country's struggling manufacturing sector. (Reporting by Ankika Biswas and Johann M Cherian in Bengaluru; Editing by Rashmi Aich, Eileen Soreng and Jane Merriman)

More News
12 Dec 2022 21:46

Amgen dives deeper into rare disease drugs with $27.8 bln Horizon deal

Dec 12 (Reuters) - Amgen Inc on Monday agreed to buy Horizon Therapeutics Plc in a deal valued at $27.8 billion, fortifying its rare diseases portfolio in the biggest buyout in the sector this year.

Read more
12 Dec 2022 17:26

European shares slip on fears over rising China COVID cases, await rate decisions

STOXX 600 down 0.5%

*

Read more
12 Dec 2022 11:25

Three-way split coming at BoE

STOXX down 0.4%, volatility hits 1-mo high

*

Read more
12 Dec 2022 10:48

What to prefer in 2023: Europe or America?

STOXX down 0.4%, volatility hits 1-mo high

*

Read more
12 Dec 2022 07:44

Europe seen weaker as more rate hikes loom

Welcome to the home for real-time coverage of markets brought to you by Reuters reporters. You can share your thoughts with us at

Read more
12 Dec 2022 06:59

Hunkering down

Welcome to the home for real-time coverage of markets brought to you by Reuters reporters. You can share your thoughts with us at

Read more
7 Dec 2022 17:43

European shares fall for fourth day on growth worries

STOXX 600 falls for the fourth straight day

*

Read more
7 Dec 2022 12:16

GSK, Sanofi shares soar as Zantac litigation fears abate

Thousands of Zantac lawsuits dismissed on Tuesday

*

Read more
7 Dec 2022 11:43

Winter is coming... and so are earnings downgrades

STOXX 600 falls 0.5%

*

Read more
7 Dec 2022 11:22

Being bearish but also bullish on Europe Inc

STOXX 600 down 0.5%

*

Read more
7 Dec 2022 09:24

Forza Italia in early Europe

STOXX 600 down 0.2%

*

Read more
7 Dec 2022 08:09

Sanofi shares rally as company avoids U.S. lawsuits over Zantac

PARIS, Dec 7 (Reuters) - Sanofi shares rose by around 8% in early Paris stockmarket trading on Wednesday after the company avoided thousands of U.S. lawsuits claiming that the heartburn drug Zantac caused cancer.

Read more
6 Dec 2022 23:12

GSK, Pfizer, Sanofi fend off thousands of U.S. lawsuits over alleged Zantac cancer link

Dec 6 (Reuters) - Drugmakers GSK Plc, Pfizer Inc , Sanofi SA and Boehringer Ingelheim on Tuesday were spared thousands of U.S. lawsuits claiming that the heartburn drug Zantac caused cancer, as a judge found the claims were not backed by sound science.

Read more
6 Dec 2022 19:51

GSK, Pfizer, Sanofi escape U.S. federal litigation over Zantac

Dec 6 (Reuters) - Drugmakers GSK Plc, Pfizer Inc , Sanofi SA and Boehringer Ingelheim on Tuesday defeated thousands of lawsuits in U.S. federal court claiming that the heartburn drug Zantac caused cancer, as a judge found the claims were not backed by sound science.

Read more
2 Dec 2022 17:15

Europe's STOXX 600 slips, but marks seventh week of gains

Sanofi slips amid Horizon deal talks

*

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.